Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02667275 · ClinicalTrials.gov registry record · Phase 3
A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis
A Phase 3 study of Seborrheic Keratosis, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 487
- Enrollment target
- 1
- Study location
NCT02667275: Completed Phase 3 study of Seborrheic Keratosis, sponsored by Aclaris Therapeutics.
NCT02667275 is a Phase 3 study of Seborrheic Keratosis that has completed, run by Aclaris Therapeutics. The registered enrollment target is 487 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02667275, a Phase 3 study of Seborrheic Keratosis, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 487 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-blind, vehicle-controlled, parallel group study.
Primary Outcome
Proportion of subjects for whom all target lesions were judged to be clear on the Physician Lesion Assessment Scale (PLA=0) at Visit 8. The Physician Lesion Assessment Scale is a 4 point scale used by the investigator to assess the subject's target sk lesions.
Conditions Studied
Interventions
- DRUG A-101 Solution
- OTHER Vehicle Solution
Study Locations (1)
Pennsylvania
- Aclaris Therapeutics, Inc. - Malvern
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 487 participants |
| Start Date | 2016-01 |
| Est. Completion | 2016-10 |
| Phase | Phase 3 |
What the finished NCT02667275 record still lists
NCT02667275 is an interventional study that assigns participants to a tested intervention. The registered 487 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (37% lower).
The record links to 1 condition, with Seborrheic Keratosis appearing as the primary indexed condition, and to 2 interventions - of which A-101 Solution is the first listed.
NCT02667275 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02667275 about?
NCT02667275 is a clinical study titled "A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis". This is a randomized, double-blind, vehicle-controlled, parallel group study.
What is the current status of trial NCT02667275?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 487 participants. The study started on 2016-01. Estimated completion is 2016-10.
What conditions does trial NCT02667275 study?
This clinical trial studies the following conditions: Seborrheic Keratosis.
What interventions are being tested in trial NCT02667275?
The interventions under investigation include: A-101 Solution (DRUG), Vehicle Solution (OTHER).
Who is sponsoring clinical trial NCT02667275?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02667275 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seborrheic Keratosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02667275's enrollment target sits among peer trials
487 786th of 2000 higher than 1,212 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06948435 · 487 participants · Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
- NCT06952530 · 487 participants · Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
- NCT05154669 · 488 participants · Phase 3
Integrating Financial Coaching and Smoking Cessation Coaching
- NCT06532877 · 488 participants · NA
Telephone Support in Advanced Gastrointestinal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia